JP6607850B2 - Ｖｅｇｆアンタゴニスト及び抗ｃｔｌａ−４抗体の組み合わせを含む方法及び組成物 - Google Patents

Ｖｅｇｆアンタゴニスト及び抗ｃｔｌａ−４抗体の組み合わせを含む方法及び組成物 Download PDF

Info

Publication number
JP6607850B2
JP6607850B2 JP2016524116A JP2016524116A JP6607850B2 JP 6607850 B2 JP6607850 B2 JP 6607850B2 JP 2016524116 A JP2016524116 A JP 2016524116A JP 2016524116 A JP2016524116 A JP 2016524116A JP 6607850 B2 JP6607850 B2 JP 6607850B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
antibody
ctla
vegf
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016524116A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016539096A (ja
JP2016539096A5 (enExample
Inventor
エラ・イオッフェ
イザレル・ロウィ
ギャビン・サーストン
エレナ・ブローヴァ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2016539096A publication Critical patent/JP2016539096A/ja
Publication of JP2016539096A5 publication Critical patent/JP2016539096A5/ja
Application granted granted Critical
Publication of JP6607850B2 publication Critical patent/JP6607850B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2016524116A 2013-10-18 2014-10-17 Ｖｅｇｆアンタゴニスト及び抗ｃｔｌａ−４抗体の組み合わせを含む方法及び組成物 Active JP6607850B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201361892601P 2013-10-18 2013-10-18
US61/892,601 2013-10-18
US201361901596P 2013-11-08 2013-11-08
US61/901,596 2013-11-08
US201461952923P 2014-03-14 2014-03-14
US61/952,923 2014-03-14
US201462055734P 2014-09-26 2014-09-26
US62/055,734 2014-09-26
PCT/US2014/061071 WO2015058048A1 (en) 2013-10-18 2014-10-17 Methods and compositions comprising a combination of a vegf antagonist and an anti-ctla-4 antibody

Publications (3)

Publication Number Publication Date
JP2016539096A JP2016539096A (ja) 2016-12-15
JP2016539096A5 JP2016539096A5 (enExample) 2017-11-09
JP6607850B2 true JP6607850B2 (ja) 2019-11-20

Family

ID=51844874

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016524116A Active JP6607850B2 (ja) 2013-10-18 2014-10-17 Ｖｅｇｆアンタゴニスト及び抗ｃｔｌａ−４抗体の組み合わせを含む方法及び組成物

Country Status (11)

Country Link
US (2) US9968674B2 (enExample)
EP (1) EP3057990B1 (enExample)
JP (1) JP6607850B2 (enExample)
KR (1) KR102338453B1 (enExample)
CN (1) CN105636986B (enExample)
AU (1) AU2014337135B2 (enExample)
CA (1) CA2926853C (enExample)
EA (1) EA037890B1 (enExample)
IL (1) IL244599B (enExample)
MX (1) MX377714B (enExample)
WO (1) WO2015058048A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2008012991A (es) 2006-04-07 2008-10-17 Procter & Gamble Anticuerpos que ligan proteina tirosina fosfatasa humana beta (hptpbeta) y los usos de estos.
EP2766043A4 (en) 2011-10-13 2015-06-10 Aerpio Therapeutics Inc METHOD FOR THE TREATMENT OF CAPILLARY LECKSYNDROME AND CANCER
CN112626125A (zh) 2014-03-17 2021-04-09 阿德夫拉姆生物技术股份有限公司 用于视锥细胞中增强的基因表达的组合物和方法
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
US11021519B2 (en) 2015-03-02 2021-06-01 Adverum Biotechnologies, Inc. Compositions and methods for intravitreal delivery of polynucleotides to retinal cones
MA44594B1 (fr) 2015-05-29 2020-09-30 Memorial Sloan Kettering Cancer Center Anticorps anti-ctla-4 et méthodes d'utilisation de ceux-ci
WO2017106462A1 (en) * 2015-12-18 2017-06-22 Biogen Ma Inc. Bispecific antibody platform
KR20250057128A (ko) 2015-12-30 2025-04-28 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
US11760803B2 (en) 2016-03-24 2023-09-19 Takeda Pharmaceutical Company Limited Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
IL279919B2 (en) * 2016-06-16 2025-01-01 Adverum Biotechnologies Inc Treating AMD using an AAV2 variant with aflibercept
KR20190031246A (ko) 2016-07-20 2019-03-25 에르피오 세러퓨틱스 인코포레이티드 VE-PTP (HPTP-β)를 표적으로 하는 인간화된 단클론성 항체
IL307242A (en) 2016-12-07 2023-11-01 Agenus Inc Anti-CTLA-4 antibodies and methods of using them
WO2018144587A1 (en) * 2017-01-31 2018-08-09 Research Development Foundation Steap2 inhibitors for the treatment of liver cancers
MA50908A (fr) 2017-11-17 2020-09-23 Amgen Inc Formulations de protéines de fusion vegfr-fc
WO2019152423A1 (en) * 2018-02-02 2019-08-08 Oncoimmune, Inc. Mutant anti-ctla-4 antibodies with improved immunotherapeutic effect but attenuated adverse effects
CA3089704A1 (en) * 2018-02-02 2019-08-08 Oncoimmune, Inc. Methods of selecting and designing safer and more effective anti-ctla-4 antibodies for cancer therapy
JP2021514656A (ja) * 2018-03-02 2021-06-17 コディアック サイエンシーズ インコーポレイテッドＫｏｄｉａｋ Ｓｃｉｅｎｃｅｓ Ｉｎｃ． Ｉｌ−６抗体ならびにその融合構築物およびコンジュゲート
SG11202010589YA (en) 2018-05-14 2020-11-27 Oncoimmune Inc Anti-cd24 compositions and uses thereof
CN113164597B (zh) 2018-09-24 2025-02-28 视点制药公司 靶向HPTP-β（VE-PTP）和VEGF的多特异性抗体
BR112021008060A2 (pt) * 2018-10-31 2021-11-23 Bioatla Inc Polipeptídeo, anticorpo anti-ctla4 ou fragmento de anticorpo, imunoconjugado, composição farmacêutica, dose única de composição farmacêutica, método de tratar câncer, e, kit para diagnóstico ou tratamento
CN111378044B (zh) * 2018-12-28 2022-07-15 长春金赛药业有限责任公司 抗体融合蛋白、制备方法及其应用
AU2020216368B2 (en) * 2019-01-30 2025-04-24 Amgen Inc. Aflibercept attributes and methods of characterizing and modifying thereof
US11912784B2 (en) 2019-10-10 2024-02-27 Kodiak Sciences Inc. Methods of treating an eye disorder

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19802753A1 (de) * 1998-01-26 1999-07-29 Merck Patent Gmbh Coreaktive Trägermaterialien zur Heterogenisierung von Katalysatoren, Cokatalysatoren und Liganden
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
US7396664B2 (en) 1999-06-08 2008-07-08 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
US7303746B2 (en) * 1999-06-08 2007-12-04 Regeneron Pharmaceuticals, Inc. Methods of treating eye disorders with modified chimeric polypeptides
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
AU784012B2 (en) 1999-08-24 2006-01-12 E. R. Squibb & Sons, L.L.C. Human CTLA-4 antibodies and their uses
IL149701A0 (en) * 2001-05-23 2002-11-10 Pfizer Prod Inc Use of anti-ctla-4 antibodies
CN101052655A (zh) * 2004-11-04 2007-10-10 辉瑞产品有限公司 用于治疗乳腺癌的ctla4抗体和芳香酶抑制剂组合物
CA2647282A1 (en) * 2006-04-05 2007-10-11 Pfizer Products Inc. Ctla4 antibody combination therapy
RU2448979C2 (ru) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
EP2212432A4 (en) * 2007-10-22 2011-10-19 Schering Corp COMPLETELY HUMAN ANTI-VEGF ANTIBODIES AND USE PROCEDURES
EP2240204A1 (en) 2008-02-04 2010-10-20 Medarex, Inc. Anti-clta-4 antibodies with reduced blocking of binding of ctla-4 to b7 and uses thereof
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2

Also Published As

Publication number Publication date
EA037890B1 (ru) 2021-06-01
WO2015058048A1 (en) 2015-04-23
KR20160067978A (ko) 2016-06-14
CN105636986A (zh) 2016-06-01
US10532096B2 (en) 2020-01-14
JP2016539096A (ja) 2016-12-15
US20180236070A1 (en) 2018-08-23
CN105636986B (zh) 2020-05-12
US20160243225A1 (en) 2016-08-25
AU2014337135B2 (en) 2019-09-19
IL244599A0 (en) 2016-04-21
EP3057990B1 (en) 2019-09-04
KR102338453B1 (ko) 2021-12-13
US9968674B2 (en) 2018-05-15
CA2926853C (en) 2022-04-26
MX377714B (es) 2025-03-11
IL244599B (en) 2019-10-31
MX2016004736A (es) 2016-07-26
EP3057990A1 (en) 2016-08-24
EA201690633A1 (ru) 2016-08-31
CA2926853A1 (en) 2015-04-23

Similar Documents

Publication Publication Date Title
JP6607850B2 (ja) Ｖｅｇｆアンタゴニスト及び抗ｃｔｌａ−４抗体の組み合わせを含む方法及び組成物
JP7775347B2 (ja) 癌治療におけるｆｇｆｒ２阻害剤単独または免疫刺激剤との組み合わせ
AU2014337135A1 (en) Methods and compositions comprising a combination of a VEGF antagonist and an anti-CTLA-4 antibody
JP6038650B2 (ja) Ｄｌｌ４アンタゴニスト及び化学療法剤を用いたがんの治療方法
JP2018532383A (ja) ヒトｔ細胞免疫グロブリン及びｉｔｉｍドメイン（ｔｉｇｉｔ）に特異的な抗体
JP2018535204A (ja) Ｃｄ８０細胞外ドメインポリペプチドと、がん治療でのそれらの使用
US20140134169A1 (en) Methods of Treating Ovarian Cancer with Dll4 Antagonists
JP2022512851A (ja) がんの処置のための抗ｔｉｇｉｔ抗体の投薬レジメン
JP2021535149A (ja) Ｃｄ１３７／ｈｅｒ２二重特異性物質とｐｄ−１系阻害物質とを含む併用療法およびその使用法
JP2022500410A (ja) 非マイクロサテライト高不安定性／ミスマッチ修復の良好な結腸直腸がんを処置するためのｐｄ−１アンタゴニストおよびｌａｇ３アンタゴニストの組み合わせ
KR20230093282A (ko) 폐암에 대한 lag-3 길항제 요법
JP2023554422A (ja) がんの治療のための多重特異性抗体
CN114450028A (zh) Lag-3拮抗剂治疗的定量空间剖析
JP2025527535A (ja) 抗ｃｃｒ８抗体およびその使用
WO2024041652A1 (en) Methods of cancer treatment
JP2020512357A (ja) 抗ｇｉｔｒ抗体を使用した癌の併用療法
WO2025106736A2 (en) Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating lung cancer
KR20250156813A (ko) 이중특이성 항-CD22 x 항-CD28 분자를 이용한 암 치료 방법
HK1227888B (en) Compositions comprising a combination of a vegf antagonist and an anti-ctla-4 antibody
HK1227888A1 (en) Compositions comprising a combination of a vegf antagonist and an anti-ctla-4 antibody

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170927

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170927

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180911

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181204

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190416

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190618

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20191008

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20191021

R150 Certificate of patent or registration of utility model

Ref document number: 6607850

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250